The company expects to mitigate fiscal 2024 challenges related to reimbursement, COVID headwinds, and enrollment at Elixir and to drive meaningful Adjusted EBITDA growth in fiscal 20. consensus of $22.88 billion, with retail pharmacy segment revenue of $17.8 billion-$18.1 billion and pharmacy services segment revenue of $3.9 billion-$4.0 billion.Īdjusted EPS loss is expected to be $(4.44)- $(4.93).Īdjusted EBITDA is expected to be $340 million and $370 million. Guidance: Rite Aid expects FY24 revenues of $21.7 billion-$22.1 billion vs. Pharmacy Services Segment revenues declined 20.8% to $1.3 billion. Total same-store prescriptions, excluding COVID immunizations , increased by 9.7%, with same-store maintenance prescriptions rising by 8.2% and other same-store acute prescriptions increasing by 14.9%. Retail Pharmacy Segment revenues increased 8.2% Y/Y to $4.79 billion due to increased acute and maintenance prescriptions. The company reported an Adjusted EPS loss of $(1.24) compared to a loss of $(2.24) a year ago and the consensus of $(0.77). The marginal change was primarily due to an extra week in the fourth quarter and increases in comparable front-end sales and non-COVID prescriptions, partially offset by a reduction in revenue from COVID vaccines and testing, store closures, and the loss of commercial clients at Elixir. Rite Aid Corp (NYSE: RAD) has reported Q4 FY23 sales of $6.09 billion, compared to $6.06 billion a year ago, beating the consensus of $5.67 billion.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |